We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Russia to Share Preliminary Results from Ongoing Phase 3 Study of COVID-19 Vaccine

By HospiMedica International staff writers
Posted on 30 Sep 2020
Print article
Illustration
Illustration
Russia plans to share the preliminary results of its COVID-19 vaccine trial based on the first six weeks of monitoring participants, according to a report by Reuters.

Russia became the first country to register a coronavirus vaccine named Sputnik V that was developed by the Gamaleya Institute of Epidemiology and Microbiology (Moscow, Russia). Preliminary results of the first two phases of clinical trials of the Sputnik V COVID-19 vaccine published in the Lancet journal confirmed that it stimulated the volunteers’ immune system to develop antibodies to SARS-CoV-2 and was safe for humans. Alexander Gintsburg, head of the Gamaleya Institute, told Reuters that there was a public interest argument for sharing interim results after 42 days as the data would indicate the general trend. In the Phase 3 trial, the first of 5,000 volunteers was vaccinated on September 9, which means that the interim results could be issued anytime after October 21.

Several vaccine makers are conducting final-stage trials since more than 42 days but are yet to publish any interim results as they prefer to wait until they have enough infections to get a reliable read-out from the data before publication. Russia’s plan to publish interim results based on the first 42 days of monitoring volunteers means that it could become the first country in the world to announce any data from a final-stage trial.

Gintsburg told Reuters that there had been no serious side-effects during the Phase 3 trial and minor, anticipated side-effects had been observed among 14% to 15% of the volunteers. Gintsburg said that the volunteers would be monitored for 180 days after the last of 40,000 participants was vaccinated. Six months after that, his team would tally up the final results and publish them in an international journal. A government source also told Reuters that the interim Phase 3 trial results would decide whether Russia would expand its ongoing mass inoculation drive, starting with people aged over 60 years. According to Gintsburg, the large number of participants totaling 40,000 would make the trial effective even with low levels of COVID-19 transmission in Moscow.

“It guarantees that even with a low infection rate, we would still have statistically significant data,” said Gintsburg.

Related Links:
Gamaleya Institute of Epidemiology and Microbiology

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Neonatal Transport Ventilator
Babylite

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.